PDF Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

[Pages:1]J A N 4 11 15

FEB 2 5

2326 M A R

15

APR 5

19

MAY 9

J U N 5 11

30 J U L

11 17 26 A U G

20 31 S E P 4

OCT 1

1517 2931 N O V

15 19

DEC

Eurofins acquires Tsing Hua

Eurofins acquires NMDL-LCPL

SGS acquires

Eurofins acquires

Labortoire de

City Analysts

Controle et d'Analyse

Eurofins acquires Labo Van Poucke

INC Research and

SGS acquires

inVentiv Health

TraitGenetics

change name to

Syneos Health

Worldwide Clinical Trials acquires Continuum's late stage practice

Cognizant acquires Bolder Healthcare Solutions

Frontage acquires Concord Biosciences

Eurofins acquires PHAST

Premier Research acquires Regulatory Professionals Inc.

Covance acquires Sciformix

Accelovance merges with Linical

Bracket merges with CRF Health

Nuvisan acquires Galderma R&D site

SGS acquires Polymer Solutions Incorporated

Synteract acquires Cu-Tech

Syneos Health acquires Kinapse

Eurofins acquires Clinical Research Laboratories

Eurofins acquires EnvironeX

Eurofins acquires Dermscan

Synteract acquires Medical Review O cers Certification Council

Oracle acquires GoBalto

Novotech Altasciences acquires CNS acquires SNBL

Synteract acquires KinderPharm

Gross revenues for the top 5, publically-listed companies by sector

PHARMA

$75 $68.6B

$71.1B

$70.9B

$72.7B

$50

$72.1B

Billions (USD)

$25

$0 Q3, 2017

CRO

$5

$3.71B

$2.5

Q4, 2017 $4.15B

Q1, 2018 $4.2B

Q2, 2018 $4.26B

Q3, 2018 $4.36B

THERAPEUTIC AREAS

Oncology was the most prevalent therapeutic area, with 17 drugs approved.

Oncology (17)

Infectious Disease (12)

Immunology (8)

(5)

Neurology (8)

Genetic Disease (6)

Gastroenterology

Billions (USD)

Musculoskeltal

Gynecology (3)

Pulmonology (4)

$0 Q3, 2017

CMO

$1.5

$1

$1.24B

Billions (USD)

$0.5

$0 Q3, 2017

Q4, 2017 $1.38B

Q4, 2017

Q1, 2018 $1.41B

Q1, 2018

Q2, 2018 $1.45B

Q2, 2018

Q3, 2018 $1.26B

Q3, 2018

Hematology (15)

Dermatology (6)

Urology (2)

MOLECULE TYPE

The Food and Drug Administration made 59 Novel Drug Approvals in 2018.

17 Biologics

42 Small Molecules

(3)

Other Therapeutic Areas (5)

24,946 studies were launched in 2018. The top locations for these are shown below.

UNITED STATES

8,617 clinical trials launched

FRANCE

1,898 clinical trials launched

CHINA

1,808 clinical trials launched

CANADA

1,332 clinical trials launched

UNITED KINGDOM

1,165 clinical trials launched

GERMANY

950 clinical trials launched

SPAIN

913 clinical trials launched

ITALY

746 clinical trials launched

SOUTH KOREA

722 clinical trials launched

BELGIUM

564 clinical trials launched

Recipharm buys out Nitin Life Sciences

Lonza US expansions announced

Almac annonces Ireland expansion

Almac UK new lab announcement

Almac opens new UK facility, Catalent completes Singapore expansion

Siegfried acquires Arena Pharma facility

Recipharm completes France expansion

WuXi Biologics announces China expansion

Almac completes US expansion

Catalent completes US expansion

Lonza opens new US facility

Catalent announces US expansion

Patheon announces US expansion

WuXi Biologics announces new Ireland facility

Lonza announces US expansion

Cambrex completes US expansion

WuXi Biologics announces new China facility

Catalent completes US expansion

WuXi Biologics announces new Singapore facility

Cambrex announces Sweden expansion

WuXi Biologics announces new US facility

Wockhardt opens new UAE facility

Recipharm completes Sanofi UK site acquisition

WuXi Biologics announces new China facility

Evonik announces US, Canada expansions

Catalent completes Juniper Pharmaceuticals acquisition

Cambrex acquires Almac completes Cambrex

Lonza completes

Halo Pharma, Lonza UK expansion announces Italy Switzerland

begins US expansion

Evonik completes US, Germany expansions;

Catalent completes Italy expansion, Lonza opens

expansion, Lonza expansion

announces Switzerland expansion

CordenPharma opens new Italy facility

invests in new Germany, Slovakia facilities

new Switzerland AMRI completes

facility

Spain expansion

Vetter

Cambrex acquires Avista Pharma

Lonza announces Cambrex

Switzerland

announces

expansion

US expansion

announces Germany expansion

WuXi Biologics breaks ground on new China facility

Catalent, Evonik announce US expansions

Lonza announces China expansion

Catalent announces China expansion

JAN 2

18 24 F E B

20 28 M A R

1215 21

APR

1012 16 242730 M A Y 4 15-17 22 31 J U N

1113 20 27 J U L

27 A U G

13

SEP

12 1920 25 O C T 24 89

24 N O V 5 8

2022 27 D E C 3 10

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download